Torpedo Pharmaceuticals AG’s Mission is to set a New Standard in Cancer Therapy with Innovative Radiopharmaceuticals

Pioneering Next-Generation Radiopharmaceuticals

Torpedo Pharmaceuticals AG aims to enhance oncology treatments through the innovative use of the radioisotope Tb-161. This therapeutic radionuclide delivers a significantly higher radiation dose to tumors compared to traditional options, potentially offering more efficient and targeted approach to cancer care (1).

Introducing Torpedo Molecules

The company is developing proprietary “torpedo molecules” that act as molecular “nuclear bombs,” precisely navigating the body to deliver targeted treatment. These molecules are designed to eradicate cancer cells effectively while sparing healthy tissue (2).

The Game-Changing Potential of Terbium-161

Tb-161’s unique properties, including the emission of conversion and Auger electrons, enable it to deliver at least three times higher radiation dose to tumors compared to traditional Lutetium-177 therapies (3). This innovative radionuclide expected to have a similar safety profile compared to the current “gold standard” Lutetium-177 based therapies (4).

Targeted Therapy with Minimal Side Effects

Unlike conventional therapies that may damage surrounding healthy tissues, radioligand therapies selectively target tumor cells, allowing a safer treatment experience due to reduced side effects and improving quality of life for cancer patients (5).

Focused Clinical Development

Torpedo Pharmaceuticals AG is committed to advancing its clinical development pipeline, supported by promising results from preclinical studies. The company is initially focusing on unmet medical needs in oncology, with plans to develop innovative therapies for prostate cancer, breast cancers, lung cancer and pancreatic adenocarcinoma.

Leadership and Expertise

Under the guidance of an experienced management team led by Dr. Nadezda Gracheva, who successfully developed Tb-161 manufacturing and produced Tb-161 for first-in-human administration, and a globally renowned advisory board of experts in nuclear medicine and oncology, Torpedo Pharmaceuticals AG is strategically positioned to deliver cutting-edge cancer therapies.

Advancing Radioligand Therapy

By bridging therapy and diagnostics, Torpedo Pharmaceuticals AG is aiming to offer precise tumor identification and treatment, enabling real-time visualization of patient responses. This integration of theranostics represents a significant leap forward in personalized medicine.

Shaping the Future of Cancer Care

Torpedo Pharmaceuticals AG is committed to transforming oncology through groundbreaking advancements in nuclear medicine and radioligand therapy (RLT). 

“Torpedo Pharmaceuticals AG aims to benefit the lives of thousands of cancer patients worldwide by providing superior oncology therapies in the form of next-generation radiopharmaceuticals”, says Dr. Nadezda Gracheva.

 

References

1. https://pubmed.ncbi.nlm.nih.gov/38505615/
2. Data in mice: Müller et al. Eur J Nucl Med Mol Imaging (2019); Compassionate use trial with good safety data: Schaefer-Schuler A et al. Theranostics, 14: 1830-1840 (2024)
3. Schaefer-Schuler A et al. Theranostics, 14: 1830-1840 (2024)
4. Ibid.
5. Pluvicto VISION trial shows 4x lower discontinuation rate due to side effects: https://us.pluvicto.com/about-pluvicto/how-pluvicto-may-help%20